Eplerenone

Drug Profile

Eplerenone

Alternative Names: CGP 30083; Epoxymexrenone; Inspra; SC 66110; Selara

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Medical University of Graz; Pfizer; Solvotrin Innovations
  • Class Antihypertensives; Heart failure therapies; Lactones; Pregnenes; Small molecules
  • Mechanism of Action Aldosterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Hypertension
  • Phase III Chronic heart failure; Primary hyperparathyroidism
  • Phase II Left ventricular dysfunction
  • No development reported Postmyocardial infarction

Most Recent Events

  • 01 Nov 2016 Pfizer terminates a phase II/III trial due to futility for Heart failure in Canada (PO) (NCT01708798)
  • 15 Mar 2016 Biomarkers information updated
  • 30 Jun 2015 Medical University of Graz and Pfizer complete a phase III trial in Primary hyperparathyroidism in Austria (ISRCTN33941607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top